TickerKhojPharmaceuticals · Pharmaceuticals: Major · NSE: WOCKPHARMA · data 2026-11-02
Wockhardt Limited
In plain words
Price: 21.6% below its 52-week high of ₹2,422.3.
Delivery: 40.8% of traded shares were kept for delivery over the last 10 sessions, against 39.5% over the last 60.
Latest results: a net profit of ₹79 cr for the quarter ended Sept 2026 (+1.3% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹3,564 cr |
| Net profit (last 12 months) | ₹409 cr |
| Sales growth, 3 years (yearly) | 7.8% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 49.3% (+0.2 pts in a year), pledged 10.0%, institutions 16.0%.
P/E 75.4, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 4.6%, ROCE 5.3%, operating margin 13.8%: how much profit it earns on the money it uses.
Debt/equity 0.45, Profit growth — and sales growth 7.8% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (4.6%).
- Promoters have pledged 10.0% of their shares.
- Expensive on earnings (P/E 75.4).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
WOCKPHARMA Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹969 crore, up 23.9% YoY and up 4.3% QoQ.
Net profit was ₹79 crore, up 1.3% YoY and down 25.5% QoQ.
Operating margin was 17.9% (22.8% a year ago).
EPS was ₹4.85, up 0.8% YoY and down 26% QoQ.
WOCKPHARMA के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹969 करोड़; पिछले साल की तुलना में 23.9% की बढ़त, पिछली तिमाही की तुलना में 4.3% की बढ़त।
शुद्ध मुनाफ़ा: ₹79 करोड़; पिछले साल की तुलना में 1.3% की बढ़त, पिछली तिमाही की तुलना में 25.5% की गिरावट।
ऑपरेटिंग मार्जिन: 17.9% (एक साल पहले 22.8%)।
EPS: ₹4.85; पिछले साल की तुलना में 0.8% की बढ़त, पिछली तिमाही की तुलना में 26% की गिरावट।
WOCKPHARMAના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹969 કરોડ; ગયા વર્ષની સરખામણીએ 23.9% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 4.3% વધારો.
ચોખ્ખો નફો: ₹79 કરોડ; ગયા વર્ષની સરખામણીએ 1.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 25.5% ઘટાડો.
ઓપરેટિંગ માર્જિન: 17.9% (એક વર્ષ પહેલાં 22.8%).
EPS: ₹4.85; ગયા વર્ષની સરખામણીએ 0.8% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 26% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
17/100 · Weak over the last ~60 sessions, data 2026-11-02
- Delivery vs usual 7/30: Delivery 40.6% over the last 20 sessions vs 34.3% in the 40 before (1.18x); shares delivered per day 0.7x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 5/15: 7 schemes hold it, about ₹80 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 10 Aug 26Results Q1 FY27 results: turned to profit vs a year ago -5.5% next session
- 4 May 26Results Q4 FY26 results: turned to profit vs a year ago +10.1% next session
- 10 Feb 26Results Q3 FY26 results: profit +321.4% YoY -0.6% next session
- 3 Nov 25Results Q2 FY26 results: turned to profit vs a year ago +6.5% next session
- 8 Aug 25Results Q1 FY26 results: loss widened vs a year ago -3.9% next session
- 29 May 25Results Q4 FY25 results: loss narrowed vs a year ago +9.6% next session
- 7 Feb 25Results Q3 FY25 results: turned to profit vs a year ago -8.0% next session
- 13 Nov 24Results Q2 FY25 results: loss narrowed vs a year ago -0.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹969 cr | ₹79 cr | +1.3% | 17.9% | 4.85 |
| Jun 2026 | ₹929 cr | ₹106 cr | — | 20.7% | 6.55 |
| Mar 2026 | ₹965 cr | ₹166 cr | — | 23.3% | 10.23 |
| Dec 2025 | ₹888 cr | ₹59 cr | +321.4% | 19.9% | 3.61 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 49.32% | 49.08% | 49.08% | 49.08% |
| Foreign institutions (FII) | 7.02% | 7.22% | 7.09% | 6.99% |
| Domestic institutions (DII) | 9.00% | 9.24% | 10.96% | 10.55% |
| Mutual funds | 5.99% | 6.79% | 8.12% | 7.76% |
| Retail investors | 19.18% | 19.47% | 18.87% | 19.06% |
| Number of shareholders | 1,73,116 | 1,66,518 | 1,39,016 | 1,42,274 |
Common questions
What was Wockhardt Limited's latest quarterly profit?
Wockhardt Limited reported a net profit of ₹79 cr for the quarter ended Sept 2026 (+1.3% on the same quarter a year earlier), on revenue of ₹969 cr.
How much do promoters hold in Wockhardt Limited?
Promoters held 49.32% of Wockhardt Limited at the end of Sept 2026, with 9.97% of promoter shares pledged.
Is Wockhardt Limited debt-free?
Its latest reported debt-to-equity ratio is 0.45.
What is Wockhardt Limited's P/E ratio?
About 75.4, based on the last 12 months' earnings and a price of ₹1,898 (data 2026-11-02).
What is the 52-week high and low of Wockhardt Limited?
The 52-week high is ₹2,422.3 and the 52-week low is ₹1,086.7.
Mutual funds holding Wockhardt Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 7 schemes holding about ₹80 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| Nippon India Nifty Pharma ETF | Nippon India Mutual Fund | 1.77% | ₹31 cr |
| Nippon India Nifty Smallcap 250 Index Fund | Nippon India Mutual Fund | 0.78% | ₹27 cr |
| SBI Nifty Smallcap 250 Index Fund | SBI Mutual Fund | 0.78% | ₹14 cr |
| ADITYA BIRLA SUN LIFE NIFTY SMALLCAP 50 INDEX FUND | Aditya Birla Sun Life Mutual Fund | 2.06% | ₹8 cr |
| Mirae Asset Nifty Smallcap 250 ETF | Mirae Asset Mutual Fund | 0.78% | ₹1 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 1.30% | ₹0 cr |
| SBI Nifty Small Cap 250 ETF | SBI Mutual Fund | 0.78% | ₹0 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Wockhardt Limited | ₹1,898 | ₹30,809 cr | 75.4 | — | 4.6% | 5.3% | 0.45 | +47.4% |
| GlaxoSmithKline Pharmaceuticals Limited | ₹2,566.8 | ₹42,073 cr | 40.7 | — | 49.1% | 52.8% | 0.01 | -2.5% |
| Emcure Pharmaceuticals Limited | ₹1,874.2 | ₹35,440 cr | 35.1 | — | 19.7% | 22.6% | 0.31 | +40.9% |
| Acutaas Chemicals Ltd | ₹3,999.2 | ₹32,770 cr | 74.9 | 17.6 | 24% | 28.9% | 0.02 | +134.8% |
| Piramal Pharma Limited | ₹241.05 | ₹31,826 cr | — | 3.9 | -4% | 1.3% | 0.7 | +19.2% |
| Neuland Laboratories Ltd. | ₹19,330 | ₹25,276 cr | 49.8 | — | 21.4% | 23.8% | 0.16 | +19.5% |
Compare WOCKPHARMA with GLAXO in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open WOCKPHARMA in TickerKhoj →